1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Kyntra Bio, Inc.

Kyntra Bio, Inc.

KYNB
Kyntra Bio, Inc.US flagNASDAQ Global Market
6.81
USD
-0.03
- -
27.57MMarket Cap
Kyntra Bio, Inc.
KYNB
(NASDAQ Global Market)

Recent

price

6.81

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
34.87
54.03
183.22
74.92
72.99
44.87
63.33
74.04
49.06
63.7
37.6
12.03
7.4
1.59
1.84
Revenue per Share
-17.22
-7.9
-79.23
-35.54
-23.14
-41.4
-25.7
-22.21
-52.67
-78.51
-78.45
-73.03
-11.89
45.38
40.45
Basic EPS, GAAP
-3.36
10.11
19.04
-8.51
2.33
-25.69
-25.03
-24.37
21.59
-30.43
-49.33
-81.59
-34.55
-1.19
-5.29
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-130.99
-138.89
-428.35
-168.82
-186.91
-215.73
-212.63
-226.2
-270.74
-341.94
-415.88
-472.99
-471.91
-421.73
-425.54
Book Value per Share
-96.54
-104.25
320.47
81.55
69.77
187.61
157.17
154.5
122.82
62.02
-0.4
-41.67
-45.89
1.11
-2.3
Tangible Book Value per Share
2
2
1
2
3
3
3
3
4
4
4
4
4
4
4
Basic Weighted Avg Shares
66
102
138
181
183
131
213
257
176
235
141
47
30
6
7
Sales/Revenue/Turnover
-41.29
-7.78
-36.41
-42.93
-27.32
-89.53
-40.71
-34.81
-108.83
-122.62
-213.9
-662.6
-442.13
-704.07
-596.1
Operating Margin (%)
6
5
4
6
6
6
7
21
22
15
11
10
3
1
- -
Depreciation Expense
-33
-15
-60
-86
-58
-121
-86
-77
-189
-290
-294
-284
-48
183
164
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-49.4
-14.63
-43.24
-47.44
-31.7
-92.27
-40.58
-30
-107.36
-123.25
-208.66
-607.29
-160.63
2,848.63
2,199.42
Profit Margin (%)
29
106
135
133
201
663
601
600
592
249
219
114
63
70
73
Working Capital
92
96
97
97
97
98
97
39
26
89
80
137
73
- -
- -
LT Debt
122
108
241
197
175
548
528
535
441
229
-1
-162
-184
4
-9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
49
35
27

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
133
99
101
Cash, Cash Equivalents & STI
118
89
87
Accounts Receivable, Net
- -
- -
5
Inventories
4
4
3
Total Current Liabilities
36
29
28
Payables & Accruals
27
21
20
ST Debt
- -
- -
- -
Deferred Revenue
5
5
6

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1,080.34%
2,124.28%
-102.44%
Free Cash Flow
-195.04%
-52.32%
-96.52%
Net Income, GAAP
-33.52%
-103.51%
-485.57%
Sales/Revenue/Turnover
-16.38%
-37.69%
-78.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
25
1
- -
-123
30
2025
3
1
1
1
6
2026
4
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-8.32
-3.89
-4.25
4.46
-11.89
2025
1.15
-1.88
49.61
-3.51
45.38
2026
-3.76
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Kerala Ayurveda Limited (KERALAYUR.BO)
MatsukiyoCocokara & Co. (MSMKF)
Shinnihonseiyaku Co., Ltd. (4931.T)
Corporativo Fragua, S.A.B. de C.V. (FRAGUAB.MX)
Evolus, Inc. (0K16.L)
Orphazyme A/S (0CUM.L)
Business
Kyntra Bio, Inc. engages in research, development, and commercialization of biopharmaceutical therapeutics focused on hypoxia-inducible factor biology and connective tissue growth factors to address serious unmet medical needs. The company discovers, develops, manufactures, and markets therapeutics addressing anemia, fibrotic diseases, cancer, and related conditions, with an emphasis on hypoxia pathways and tissue remodeling. Primary products and services include small molecule and biologic therapeutics targeting hypoxia-inducible factors, prolyl hydroxylase inhibitors, and candidates addressing anemia of chronic disease and myelodysplastic syndromes, alongside companion diagnostics and research collaborations. Geographically, Kyntra Bio operates across North America, Europe, and Asia-Pacific regions, with headquarters in San Francisco, California, United States, and a workforce focused on early-stage discovery through late-stage development, regulatory strategy, and commercialization support. Since its founding in 1993, the company maintains subsidiary and partner relationships to advance clinical programs, manufacturing capabilities, and strategic alliances with biopharmaceutical and biotechnology entities. Recent developments include strategic partnerships and collaborations, ongoing or recently completed funding rounds or acquisitions, and new product launches or service offerings that expand its therapy portfolio and research capabilities. The company’s business segments span discovery, preclinical and clinical development, regulatory affairs, medical affairs, manufacturing, and commercial operations, serving pharmaceutical and biotechnology customers, healthcare providers, and patients seeking innovative treatments. Foundationally, Kyntra Bio emphasizes a pipeline driven by hypoxia pathway modulation and connective tissue growth factor biology, with ongoing efforts to broaden its global reach through expanded geographic access and strategic alliances. This description reflects current publicly available information on Kyntra Bio, Inc. and its corporate activities.

Company News

APIChat

  • seekingalpha.com

    Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript

  • zacks.com

    Kyntra Bio (KYNB) Reports Q1 Loss, Tops Revenue Estimates

  • globenewswire.com

    Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

  • globenewswire.com

    Kyntra Bio to Report First Quarter 2026 Financial Results

  • zacks.com

    Kyntra Bio (KYNB) Upgraded to Buy: Here's What You Should Know

  • globenewswire.com

    Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference

  • seekingalpha.com

    Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript

  • globenewswire.com

    Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

  • zacks.com

    Kyntra Bio (KYNB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

  • globenewswire.com

    Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results

  • benzinga.com

    What's Going On With Kyntra Bio Stock Tuesday?

  • globenewswire.com

    Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026

  • globenewswire.com

    FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum

  • seekingalpha.com

    FibroGen, Inc. (FGEN) Q3 2025 Earnings Call Transcript

  • zacks.com

    FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates

  • globenewswire.com

    FibroGen to Report Third Quarter 2025 Financial Results

  • globenewswire.com

    FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

  • globenewswire.com

    FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

  • globenewswire.com

    FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

  • seekingalpha.com

    FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript